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ABSTRACT 22 
The conservative treatment of osteoarthritis (OA) of the hip is essentially symptomatic, seeking 23 
to relieve pain and optimize function. Despite presenting great clinical effect, hip arthroplasty 24 
may have restrictions, and in these situations, the neurolytic blockade of the anterior branch of 25 
the obturator nerve can be a therapeutic alternative, since it stops the afferent pain from the hip 26 
joint. Objective: To describe the results of treating patients with severe OA of the hip by applying 27 
phenol to the obturator nerve. Method: Twelve consecutive patients with OA of the hip, 28 
refractory to conservative treatment, were recruited to have the obturator nerve localized 29 
through electrostimulation and blocked with phenol. They were evaluated in terms of pain 30 
intensity via the visual analogue scale (VAS), pressure dolorimetry in the medial and lateral 31 
gluteus medius, gluteus minimus, and piriformis, and quality of life by the Harris Hip Score (HHS) 32 
at baseline (BL) after 1 (M1), 2 (M2), and 6 months (M6). Results: The patients were between 33 
30 and 72 years old with an avarege of 47.5 ± 1.7 years old, 5 of them were women. Three 34 
patients were excluded for not being able to come for follow up evaluations.  VAS values vaieded 35 
from 8.2 ±.0.9 at BL to 6.6 ± 1.7 at M1, 6.5 ± 1.7 at M2, and 7.3 ± 1 in M6 (p=0.0094). As to the 36 
HHS, the values were BL:33.27 ± 2.9; M1:39.2 ± 6.4; M2:40.2 ± 8.1, and M6: 38.8 ± 9.7 in the 37 
final evaluation (p=0,040). For dolorimetry, non significant variation was BL: 11±5.7, M1: 38 
7.9±2.2; M2: 10.9±5.6; M6: 8.1 ± 1.6 (p 0.69). Conclusion: The application of phenol to the 39 
anterior branch of the obturator nerve can be an alternative in the treatment of severe OA of the 40 
hip in patients with restrictions to Total Hip Replacement (THR), since it reduces pain and 41 
improves quality of life.  42 
 43 
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O tratamento conservador da osteoartrite (OA) do quadril é essencialmente sintomático, 47 
visando alívio da dor e otimização da funcionalidade. Apesar de apresentar grande efeito 48 
clínico, a artroplastia quadril pode ter restrições, nestas situações o bloqueio do ramo anterior 49 
do nervo obturador (RAO) pode ser uma alternativa terapêutica, uma vez que interrompe a 50 
aferência dolorosa da articulação do quadril. Objetivo: Descrever os resultados do tratamento 51 
de pacientes com OA grave do quadril por meio da aplicação de fenol no nervo obturatório. 52 
Método: Nove pacientes com OA de quadril resistente ao tratamento conservador que se 53 
apresentaram consecutivamente ao nosso serviço foram submetidos à aplicação de fenol no 54 
nervo obturatório com localização por meio de eletroestimulação e avaliados quanto a 55 
intensidade de dor pela escala visual analógica (EVA), dolorimetria de pressão e qualidade de 56 
vida pelo Haris Hip Score (HHS) após 01, 02 e 06 meses. Resultados: Foram selecionados 12 57 
pacientes que preenchiam os critérios de inclusão e exclusão, destes, 3 foram excluídos após 58 
não conseguirem mais comparecer para as avaliações. Os valores médios de EVA variaram de 59 
8,2 ±.0,9 na medida basal para 6,6 ± 1,7 ao final de um mês, 6,5 ± 1,7 ao final de dois meses 60 
e 7,3 ± 1 com 06 meses (p=0,0094). Quanto ao HHS, os valores foram 33,27 ± 2,9; 39,2 ± 6,4; 61 
40,2 ± 8,1 e 38,8 ± 9,7, na avaliação final. A última variável analisada foi a Dolorimetria, onde 62 
foi realizada a média entre os valores atingidos pela avaliação com o dolorímetro no glúteo 63 
médio medial, glúteo médio lateral, glúteo mínimo e piriforme. Na avaliação inicial média de 64 
11±5,7, 7,9±2,2 no final do primeiro mês, 10,9±5,6 no segundo e no 6º mês 8,1±1,6. Ao 65 
aplicarmos o teste ANOVA, não foi observado diferença estatística (p 0,69). Conclusão: A 66 
aplicação de Fenol em RAO pode ser uma alternativa no tratamento da OA de quadril grave 67 
em pacientes com restrições à realização de ATQ, pois implica em redução da dor e melhora 68 
da qualidade de vida. 69 
 70 
Palavras-chave: Osteoartrite do Quadril, Dor, Reabilitação, Terapêutica, Fenol, Qualidade de 71 
Vida 72 
 73 
INTRODUCTION 74 
 75 
The conservative treatment of osteoarthritis (OA) of the hip is essentially symptomatic, seeking 76 
to relieve pain and optimize function.1 The consensus for therapy consists of non-77 
pharmacological treatments such as exercise, correcting misalignments, and pharmacological 78 
treatments such as analgesics, anti-inflammatory drugs, opioids, capsaicin cream, and 79 
injections with glucocorticoids and hyaluronic acid.2  80 
 81 
When the clinical treatment fails, a surgical approach with hip arthroplasty may be 82 
recommended. The greatest concern is that the surgery is major and can be risky for patients 83 
with other diseases. As osteoarthritis of the hip is common in older age groups and in patients 84 
with greater body weight, the prevalence of comorbidities that may increase surgical risk is also 85 
greater.3 In these cases the use of a conservative treatment may be advisable, even if less 86 
efficient, because of safety issues and morbidity.  87 
 88 
Another problem that afflicts patients in the Brazilian health system is the lack of resources, 89 
which results in a lack of surgical material and long waiting lists for surgical intervention. Under 90 
these conditions the neurolytic blockade of the obturator nerve can be used as a palliative 91 
analgesic therapy.4 92 
 93 
Greater duration of the blockade can be achieved if drugs capable of harming the nerve axons 94 
are used. Phenol has an immediate local anesthetic action, due to its immediate selective effect 95 
on smaller nerve fibers.5,6 96 
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OBJECTIVE 97 
 98 
This study sought to describe the results of treating patients with severe osteoarthritis of the hip, 99 
refractory to conservative treatment, for pain relief and quality of life, through the application of 100 
phenol to the anterior branch of the obturator nerve. 101 
 102 
METHOD 103 
 104 
This study was approved by the research ethics committee of the institution, and all participants 105 
signed the free and informed consent form. Consecutive outpatients followed in the HCRP hip 106 
clinic were recruited if they met the following inclusion criteria:  107 
 108 
• Older than 18 years-old.  109 
• Both genders. 110 
• Diagnosed with osteoarthritis of the hip (hip pain associated with at least two of the following: 111 
VHS<20mm/h, osteophytes in the femur or acetabulum or reduction of articular Reduction of 112 
joint space in the acetabulum in rx). 113 
• Failure of conservative treatments with therapeutic exercise, modalities, walking aids, 114 
remedies (analgesics or anti-inflammatory drugs), or with trigger-point blockades.  115 
• Pain assessed by the Visual Analogue Scale greater than 6 at the time of evaluation. 116 
• Not having any known allergy to phenol or uncontrolled coagulopathy.  117 
 118 
The exclusion criteria were: 119 
 120 
• Having been submitted to total hip replacement (THR) or any other surgical procedure in the 121 
lower limbs after inclusion in the study. 122 
• Limited understanding of the procedures or evaluation instruments. 123 
• Difficulty in clinical follow-up or coming in for evaluations for any reason. 124 
 125 
In this study, patients were evaluated at the time of recruitment as well as immediately before 126 
the phenolic blockade (baseline - BL), then at 1 month (M1), 2 months (M2), and 6 months (M6) 127 
after the intervention. The following assessment instruments were used: 128 
 129 
• The visual analogue scale (VAS), which consists of a straight line of 100 mm anchored at the 130 
ends in the expressions 'no pain' and 'worst pain possible' on which the patient indicates the 131 
intensity of their pain symptom. The intensity of the pain is considered as the distance in 132 
centimeters from the end 'no pain' to the point where the patient has indicated his pain.7 133 
 134 
• Pressure dolorimetry (PD) is the imposing of progressively more intense pressure at a steady 135 
rate of about 1 kgf/cm2/s, on trigger points identified by muscle palpation, with a 136 
dynamometer that has a circular, rubberized 1cm2 standardized end until the patient 137 
manifests pain.7   138 
 139 
• The functional questionnaire Harris Hip Score (HHS) consists of four items: pain in the 140 
affected joint, function, presence or absence of deformity, and the range of motion of this 141 
joint. The function is assessed by asking about the patient’s activities of daily living and gait, 142 
whether the patient presents with claudication or needs external support, and the maximum 143 
distance he can walk. The score may range from 0 to 100, where the lower the score, the 144 
greater the functional impairment of the patient.8 145 
 146 
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The treatment was performed with application of phenol in the anterior branch of the obturator 147 
nerve. A Braun Stimuplex HNS 12 electrostimulator was used along with a Stimuplex A 148 
0.8X75mm needle which was inserted two fingers from the inguinal region, just below the ventral 149 
muscle of the adductor longus, with the tip of the needle pointing to the antero superior iliac 150 
spine on the same side.  151 
 152 
An electrical current of 2mA and 1 Hz helped to locate the nerve, which resulted in rhythmic 153 
contraction of the adductor muscles concomitant in the same frequency. Maintenance of 154 
contractions after decrease of current intensity to 1mA confirmed the tip of the needle positioned 155 
in close contact with the obturator nerve. Nerve block consisted in the injection of 2.5ml of 6% 156 
phenol. After the application, the patient was also evaluated on whether or not he needed gait 157 
support, to continue the therapeutic measures in use, and was counselled as to analgesics and 158 
maintaining physiotherapy, if necessary.    159 
 160 
Quantitative variables were assessed for normality by the Kolmogorov-Smirnoff and described 161 
by the mean and standard deviation. Categorical variables were grouped into categories and 162 
expressed in percentages. Any incomplete data from clinical follow-up spreadsheets were filled 163 
in a conservative manner with the LOCF technique (last observation carried forward). The 164 
clinical measures of the effect of therapeutic intervention were analyzed by ANOVA for repeated 165 
measures and, where significant, there was a post hoc comparison between moments of 166 
evaluation by the paired t test. The significance level was 0.05. 167 
 168 
RESULTS 169 
 170 
Twelve patients were selected who met the inclusion and exclusion criteria and agreed to 171 
participate. The patients were between 30 and 72 years of age, with an average of 47.45± 1,7; 172 
time with the disease between 2 and 16 years, with failures in conservative treatment using 173 
analgesics such as dipyrone, paracetamol, tramadol and codeine, as well as physiotherapy with 174 
THR recommended. One month after the procedure one patient could no longer participate in 175 
the study, followed by 2 other patients after the third evaluation, due to transportation problems. 176 
 177 
Among the 12 patients at the beginning of the study, 5 were female and 7 males. After the 178 
application, all patients reported improvement of symptoms. Only one patient reported loss of 179 
motor strength in the adductor muscles: a foreseeable side effect of the procedure.   180 
 181 
Concerning pain intensity, in the initial assessment, prior to the application of phenol to the 182 
anterior branch of the obturator nerve, the patients had a mean of 8.2 ± 0.9. with a drop to 6.6± 183 
1.7 and remained stable with a slight increase in the sixth month (7.3±1). A p-value of 0.009 was 184 
found when the ANOVA test was applied. When the results were analyzed in relation to the 185 
HHS, a baseline mean of 33.27±2.9 was found in the HHS, with improvement of the score after 186 
the first and second month, and a slight decrease in the sixth month (38.8±9.7) and p-value of 187 
0.040.   188 
      189 
The last variable analyzed was for dolorimetry, where the mean of the values was calculated for 190 
the assessment of pain in the medial and lateral gluteus medius, gluteus minimus, and piriformis. 191 
In the baseline evaluation they showed a mean of 11±5.6 and a worsening of the score in the 192 
evaluation after 1 month (7.9±2.2) and slight improvement afterwards (8.1±1.6 in the sixth 193 
month). When applying the ANOVA test, there was no statistical difference observed (p 0.69) 194 
(Table 1). 195 
 196 
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Table 1. Clinical evolution of patients with hip osteoarthritis in a 6 months period following the 197 
application of phenol to the anterior branch of the obturator nerve 198 
 199  
Baseline Month 1 Month  2 Month 6 P 
N 12 12 11 9 
 
EVA 8,2 ± 0,9 6,6 ± 1,7* 6,5 ± 1,7* 7,3 ± 1,0* § 0,009 
HHS 33,0 ± 2,9 39,2 ± 6,4* 40,2 ± 8,1* 38,8 ± 9,7* 0,04 
DP 11,0 ± 5,7 7,9 ± 2,2 10,9 ± 5,6 8,1 ± 1,6 0,694 
Legend — VAS: visual analogue scale; HHS: Harris Hip Score. PD: pressure dolorimetry: * difference in relation 200 
to the baseline value p<0.05; §: difference between 2 and 6 months p<0.05 201 
 202 
DISCUSSION 203 
 204 
Nerve blockades are therapeutic strategies in the treatment of chronic pain. Nerve blockades 205 
can be applied when a patient presents pain in joints or even muscles. The alleged therapeutic 206 
mechanism is the interruption the nociceptive path from their origin, blocking the conduction of 207 
nerve impulses.9 The analgesic effect of these procedures may be permanent or temporary by 208 
interrupting the vicious cycle of pain. 209 
 210 
Phenol has been used in the treatment of pain since 1936 as a neurolytic agent applied via 211 
intrathecal or epidural routes, or directly on the nerves.6,10 It causes nerve destruction by 212 
inducing protein precipitation. There is a loss of cellular elements, separation of the myelin 213 
sheath from the axon and axonal edema. The substance takes immediate effect by its selective 214 
effect on small nerve fibers.11 Because of these properties, phenol was chosen for the neurolysis 215 
of the anterior branch of the obturator nerve. In a study conducted by Monagle & Ee6 a 3ml intra-216 
articular injection was applied to the hip, with improvement of pain and mobility, and after 1 year 217 
the patient was sent for a repeat procedure.  218 
 219 
Silva et al.4 blocked the obturator nerve with 10ml of 0.25% bupivacaine and obtained a 100% 220 
improvement in the pain and function of one patient after the procedure, who reported 221 
independence for all activities, with the analgesic effect lasting for 40 days.  222 
 223 
The patients in the present study had severe OA of the hip, were refractory to clinical treatment, 224 
and complained of severe pain and many functional limitations. The results showed pain 225 
improvement by patients, who complained about intense pain, especially during the first 2 226 
months after the blockade, with a difference of 2 points from the initial VAS and a subsequent 227 
stabilization. But in the third assessment there was a slight regression of the score, concurrent 228 
with the patients complaining of pain once again, a fact that may be related to the duration of 229 
the phenol effect, since its effects are not permanent and a functional re-innervation occurs over 230 
a period of months-usually between 2 and 6 months. The time of action of this procedure varies 231 
with the concentration, injected volume, duration of exposure, and injection technique.  232 
 233 
If the phenol is injected near nerves that have a predominance of sensory fibers, it may cause 234 
dysesthesia or anesthesia that can last up to 4 months.12 In the study there was only one 235 
complain about side effects, 1 patient said that felt lost of motor strength but no lost in function 236 
and no dysesthesia. The improvement in the HHS happened in terms of mobility, with larger 237 
angles achieved in goniometry, as well as in the perception of ease in activities like tying shoes, 238 
taking a bus, and going up and down stairs.  239 
 240 
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Regarding the dolorimetry parameter, although no statistical difference was found, the patients 241 
presented a mild worsening of pain perception which, according to Imamura et al.13 can be 242 
associated with the myofascial pain syndrome, a condition associated with weakness and 243 
muscle shortening, which is common in patients with OA of the hip, especially in the areas being 244 
evaluated such as the piriformis, gluteus medius and minimus, and hip adductor muscles. The 245 
patients in the study had struggle with pain for long periods of time, already with a chronic pain, 246 
affecting other joints, altering the dynamic of walk and resulting in more myofascial syndrome. 247 
 248 
The present study had some limitations, such as the lack of a control group and the sample size. 249 
Another bias was the large number of comorbidities in the patients, with many already having 250 
osteoarthritis elsewhere, such as gonarthrosis and widespread pain, which affects the pain 251 
perception of the patient and would require a more comprehensive treatment; this would include 252 
providing gait supports, which in the Brazilian Health System can take up to 6 months to obtain, 253 
or the need to continue with physical therapy, where there is also a lack of time slots and 254 
professionals in the public network. 255 
 256 
CONCLUSION 257 
 258 
The application of phenol to the anterior branch of the obturator nerve can alleviate the pain and 259 
improve the quality of life in patients with hip OA, being an alternative treatment for patients who 260 
have not undergone THR, either because they lack the clinical conditions or because of long 261 
waiting lists for the procedure.  262 
 263 
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